Press release
Global Urticaria Pipeline Expands With 20+ Companies Advancing 25+ Therapies, Reveals DelveInsight's Clinical and Developmental Analysis
Urticaria Pipeline
The report delivers a comprehensive commercial and clinical analysis of pipeline therapies, spanning preclinical research to marketed products. It offers detailed drug profiles covering mechanisms of action, clinical study updates, regulatory milestones, and product development activities, including technology platforms, partnerships, collaborations, acquisitions, funding, designations, and other relevant updates.
According to DelveInsight's latest evaluation, the global Urticaria pipeline features more than 20 key pharmaceutical companies actively developing over 25 therapeutic candidates. The extensive analysis covers clinical trials, drug mechanisms, routes of administration, and ongoing research and development activities.
Download free Urticaria sample report @ https://www.delveinsight.com/sample-request/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Urticaria Pipeline Report
• Global pharmaceutical companies continue to make significant progress in advancing novel therapies for Urticaria.
• Leading companies developing Urticaria treatments include Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly, Genentech, GI Innovation/Yuhan, Regeneron, GSK, Taiho Pharma, Glenmark, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Synermore Biologics, UCB Biopharma, United BioPharma, and others.
• Promising therapies currently in clinical development-such as Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab, UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, and Desloratadine-are expected to reshape the Urticaria treatment landscape in the coming years.
Recent Urticaria Market Developments
• September 2025: A review published in Allergy highlighted positive Phase 3 outcomes for omalizumab, dupilumab, and BTK inhibitor remibrutinib in chronic spontaneous urticaria (CSU), confirming strong efficacy and clinical value.
• September 2025: Sanofi and Regeneron received a positive CHMP opinion recommending EU approval of Dupixent for moderate-to-severe CSU in patients aged 12+ who remain uncontrolled on antihistamines.
• January 2025: Jasper Therapeutics reported encouraging preliminary Phase 1b/2a results for briquilimab in CSU, demonstrating rapid and substantial reductions in UAS7 scores and early complete responses across dose groups.
• September 2024: The LIBERTY-CUPID Phase III trial validated the effectiveness of Dupixent in uncontrolled, biologic-naïve CSU patients.
• June 2024: Celldex announced that barzolvolimab achieved significant improvement in angioedema in its Phase II CSU study.
• May 2024: Novartis published long-term data supporting the safety and efficacy of remibrutinib for CSU.
• Additional clinical progress was reported by Evommune, ARS Pharmaceuticals, and Jasper Therapeutics in various urticaria subtypes.
Get a Free Sample PDF Report to know more about Urticaria Pipeline Therapeutic Assessment - https://www.delveinsight.com/report-store/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Urticaria Overview
Urticaria, or hives, is characterized by sudden, itchy, red welts that may merge to form larger patches. The condition can present as acute (less than six weeks) or chronic (persisting beyond six weeks), with significant effects on quality of life.
Emerging Urticaria Treatments in Development
The pipeline includes promising drugs across multiple phases, such as:
• Ligelizumab (Novartis)
• Remibrutinib (Novartis)
• Tezepelumab (Amgen)
• CDX-0159 (Celldex)
• GI-301 (GI Innovation)
• Dupilumab (Sanofi/Regeneron)
• UB-221 (United BioPharma)
...and many more.
Urticaria Route of Administration & Molecule Types
Urticaria Pipeline therapies are being developed across various ROAs, including:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule types span recombinant fusion proteins, monoclonal antibodies, small molecules, peptides, polymers, and gene therapy candidates.
Further Urticaria product details are provided in the report. Download the Urticaria pipeline report to learn more about the emerging Urticaria therapies - https://www.delveinsight.com/sample-request/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Urticaria Pipeline Assessment Coverage
The report evaluates:
• Products by stage (late, mid, early, preclinical, discontinued)
• Route of administration
• Molecule type
• Mechanism of action
• Monotherapy vs. combination therapy
• Collaborations, licensing, and financing activities
Urticaria Market Drivers
• Side effects of existing treatments
• Rising R&D investments
• Growing market size
• High unmet need in chronic forms of the disease
Urticaria Market Barriers
• Limited understanding of disease pathology
• Patent expiries
• Clinical and regulatory challenges
Download Sample PDF Report to know more about Urticaria drugs and therapies - https://www.delveinsight.com/sample-request/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Urticaria Pipeline Report
• Coverage: Global
• Key Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
• Key Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
• Urticaria Therapeutic Assessment: Urticaria current marketed and Urticaria emerging therapies
• Urticaria Market Dynamics: Urticaria market drivers and Urticaria market barriers
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Urticaria Pipeline Expands With 20+ Companies Advancing 25+ Therapies, Reveals DelveInsight's Clinical and Developmental Analysis here
News-ID: 4310602 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Urticaria
Chronic Idiopathic Urticaria Market Insights and Future Outlook
Chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), is a persistent skin condition characterized by recurrent hives and itching lasting six weeks or longer without an identifiable trigger. While not life-threatening, the disease has a major impact on patients' quality of life due to discomfort, sleep disturbances, and psychological distress.
Conventional antihistamines and corticosteroids remain the mainstay of treatment, but biologics such as omalizumab (Xolair) and investigational therapies…
Chronic Spontaneous Urticaria (CSU) Market Massive Growth opportunity Ahead
Introduction
Chronic Spontaneous Urticaria (CSU) is a persistent skin condition characterized by recurrent itchy hives, swelling, and inflammation lasting for six weeks or longer without any identifiable external trigger. The disease severely impacts quality of life, with patients experiencing physical discomfort, sleep disturbances, and psychological stress.
Traditionally managed with antihistamines and corticosteroids, the treatment paradigm has shifted in recent years toward monoclonal antibodies, biologics, and novel immunomodulatory drugs. Rising awareness, increasing prevalence,…
Chronic Spontaneous Urticaria: A Leading Driver Behind Impact Of Increasing Alco …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Chronic Spontaneous Urticaria Industry Market Size Be by 2025?
There has been a robust growth in the chronic spontaneous urticaria market in the past few years. It is projected to escalate from $2.06 billion in 2024 to $2.23 billion in 2025, rising at a compound annual…
Impact Of Increasing Alcohol Consumption On The Chronic Spontaneous Urticaria Ma …
The Chronic Spontaneous Urticaria Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Chronic Spontaneous Urticaria Market?
The chronic spontaneous urticaria market is expected to grow from $2.06 billion in 2024 to $2.23 billion in 2025, at a compound annual…
Chronic Urticaria Medicine Market Outlook and Future Projections for 2030
The chronic urticaria medicine market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "Chronic Spontaneous Urticaria Pipeline Insight, 2024," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Chronic Spontaneous Urticaria Research.…
